Composition with UVB damage resisting function, skin care product and application

Abstract

The embodiment of the invention discloses a composition with an anti-UVB damage function, a skin care product and application. The composition and the skin care product can be used for solving the anti-UVB damage problem. The composition comprises: a first compound selected from a compound represented by a formula (I) or a formula (II); and a second compound, wherein the second compound is selected from any one of palmitoyl tripeptide-5, acetyl dipeptide-1 cetyl ester, acetyl tripeptide-30 citrulline, and palmitoyl pentapeptide-4.

Description

Technical Field

[0001] The present invention relates to the technical field of anti-UVB damage, and particularly to a composition, a skin care product and uses thereof having the function of anti-UVB damage. Background Art

[0002] UVB (full English name: ultraviolet radiation b) is a kind of ultraviolet ray, also known as medium-wave erythema effect ultraviolet ray. UVB has a stimulating effect on the human skin, and excessive exposure to UVB can cause skin cell damage.

[0003] Therefore, the problem of damage caused by UVB irradiation remains an issue to be solved. Summary of the Invention

[0004] An object of an embodiment of the present application is to solve at least one of the above-mentioned backgrounds and provide corresponding beneficial effects.

[0005] Another object of an embodiment of the present application is to provide a composition, a skin care product and uses thereof having the function of anti-UVB damage, which can be used to solve the technical problem of anti-UVB damage.

[0006] The embodiments of the present application mainly achieve the above objects through the following technical solutions.

[0007] In one aspect, an embodiment of the present application provides a composition, comprising:

[0008] A first compound, the first compound is selected from the compounds represented by formula (I) or formula (II);

[0009] Formula (I):

[0010] Formula (II): and

[0011] A second compound, the second compound is selected from any one of palmitoyl tripeptide-5, acetyl dipeptide-1 cetyl ester, acetyl tripeptide-30 citrulline, and palmitoyl pentapeptide-4.

[0012] In yet another aspect, an embodiment of the present application provides a use of the composition in the preparation of an anti-UVB damage preparation.

[0013] In yet another aspect, an embodiment of the present application provides a use of the composition in the preparation of a DNA damage inhibitor.

[0014] In yet another aspect, an embodiment of the present application provides a use of the composition in the preparation of an HMGB1 expression inhibitor.

[0015] In another aspect, an embodiment of the present application provides a use of the described composition in the preparation of an SLC7A11 expression promoter.

[0016] In another aspect, an embodiment of the present application provides a skin care product, comprising:

[0017] a first compound, the first compound being selected from the compounds represented by formula (I) or formula (II); and

[0018] a second compound, the second compound being selected from any one of palmitoyl tripeptide-5, acetyl dipeptide-1 cetyl ester, acetyl tripeptide-30 citrulline, and palmitoyl pentapeptide-4.

[0019] The beneficial effects of the embodiments of the present invention include:

[0020] In some embodiments, the composition provided by the embodiments of the present application comprises a first compound and a second compound, and has the function of resisting UVB damage, which can solve the problems in the background; specifically, through the synergistic effect generated by the combination of the first compound and the second compound, this composition can reduce the damage of skin cells caused by UVB irradiation, and achieve the effect of resisting UVB damage.

[0021] In some embodiments, through the synergistic effect of the first compound and the second compound, the composition provided by the embodiments of the present application can resist UVB damage, and further play a role in protecting the skin.

[0022] In some embodiments, the composition provided by the embodiments of the present application can protect the skin by resisting UVB damage, and can be used to avoid or treat one or more skin diseases caused by UVB irradiation.

[0023] In some embodiments, when the first compound is selected from the compounds represented by formula (I) and the second compound is selected from any one of palmitoyl tripeptide-5, acetyl dipeptide-1 cetyl ester, acetyl tripeptide-30 citrulline, and palmitoyl pentapeptide-4, the composition provided by the embodiments of the present application can synergistically reduce the HMGB1 expression level in keratinocytes after UVB irradiation through the first compound and the second compound, and achieve an anti-inflammatory effect.

[0024] In some embodiments, when the first compound is selected from the compounds represented by formula (II) and the second compound is selected from any one of palmitoyl tripeptide-5, acetyl dipeptide-1 cetyl ester, acetyl tripeptide-30 citrulline, and palmitoyl pentapeptide-4, the composition provided by the embodiments of the present application can synergistically increase the SLC7A11 expression level in keratinocytes after UVB irradiation through the first compound and the second compound, and achieve an anti-inflammatory effect.

[0025] In some embodiments, the embodiments of the present application provide a use of the described composition in the preparation of an anti-UVB damage preparation. By reducing HMGB1 or increasing the expression of SLC7A11, the effect of anti-UVB damage can be achieved. Description of the Drawings

[0026] Figure 1 It is a nuclear magnetic schematic diagram of the compound shown in formula (I) in the embodiments of the present application;

[0027] Figure 2 It is a mass spectrum of the compound shown in formula (I) in the embodiments of the present application;

[0028] Figure 3 It is a nuclear magnetic schematic diagram of the compound shown in formula (II) in the embodiments of the present application;

[0029] Figure 4 It is a mass spectrum of the compound shown in formula (II) in the embodiments of the present application. Detailed Embodiments

[0030] The following further describes the present invention in detail with reference to the drawings, so that those skilled in the art can implement it according to the description in the specification.

[0031] The terms "first", "second", etc. in the embodiments of the present application are only for descriptive purposes, and cannot be understood as indicating or implying relative importance or implicitly indicating the quantity of the indicated technical features. Thus, the features defined with "first", "second", etc. may explicitly or implicitly include at least one of these features.

[0032] Furthermore, the terms "comprising", "containing", "having" and any variations thereof are intended to cover non-exclusive inclusion. For example, a process, method, system, product or device that includes a series of steps or units is not limited to the listed steps or units, but optionally further includes steps or units not listed, or optionally further includes other steps or units inherent to these processes, methods, products or devices.

[0033] In addition to the above, it should still be emphasized that referring to "embodiments" in this article means that the specific features, structures or characteristics described in connection with the embodiments can be included in at least one embodiment of the present application. The appearance of this phrase in various positions in the specification does not necessarily refer to the same embodiment, nor is it an independent or alternative embodiment mutually exclusive with other embodiments. Those skilled in the art explicitly and implicitly understand that the embodiments described herein can be combined with other embodiments.

[0034] <Composition>

[0035] In a first aspect, an embodiment of the present application provides a composition in the first aspect, comprising:

[0036] A first compound, the first compound being selected from the compounds represented by formula (I) or formula (II);

[0037] Formula (I):

[0038] Formula (II): and

[0039] A second compound, the second compound being selected from any one of Palmitoyl Tripeptide-5, Acetyl Dipeptide-1 Cetyl Ester, AcetylTripeptide-30 Citrulline, and Palmitoyl Pentapeptide-4.

[0040] The composition of the embodiment of the present application comprises a first compound and a second compound, and has the function of resisting UVB damage; specifically, through the synergistic effect generated by the combination of the first compound and the second compound, the composition can reduce the damage of skin cells caused by UVB irradiation, thereby overcoming the defects in the background art.

[0041] In addition, excessive irradiation of the skin with UVB can lead to the occurrence of inflammation. The composition of the first aspect embodiment can reduce the inflammation of skin cells (keratinocytes) caused by UVB irradiation through resisting UVB damage, achieving an anti-inflammatory effect, so it can further play a role in protecting the skin.

[0042] In addition, the occurrence of skin inflammation can even lead to the occurrence of various skin diseases. Therefore, it can be understood that the composition of the first aspect embodiment can protect the skin by resisting UVB damage and can be used to avoid or treat one or more skin diseases caused by UVB irradiation of the skin.

[0043] In some embodiments, the skin cells are keratinocytes (abbreviated as HaCaT).

[0044] More specifically, according to different selections of the first compound and the second compound, the composition of the embodiment of the present application can be selected from any one of the first composition to the eighth composition.

[0045] HMG1 (high mobility group 1 protein, HMG1) was first extracted and identified from bovine thymus in 1973 and got its name because of its high mobility in polyacrylamide gel electrophoresis. HMG can be further divided into three families: HMGA, HMGB, and HMGN. The HMGB family has three members, namely HMGB1, HMGB2, and HMGB3. HMGB1 (high mobility group protein B1) is the most abundant HMG protein. Existing studies have shown that HMGB1 is a typical damage-associated molecular pattern (DAMP) signal. When cells are damaged by DNA (such as radiation, chemical damage, etc.), HMGB1 will be released extracellularly and become a common marker of necrotic inflammation. And UVB irradiation can lead to high-level expression of HMGB1.

[0046] In some embodiments, when the composition is selected from any one of the first composition, the second composition, the third composition, and the fourth composition, it can reduce the HMGB1 expression level increased by UVB irradiation in keratinocytes, reduce the inflammatory response, and achieve the effect of anti-UVB damage.

[0047] In some examples, the composition is selected from the first composition, wherein the first compound is selected from the compounds shown in formula (I), and the second compound is selected from palmitoyl tripeptide-5; the first compound and the second compound can synergistically reduce the HMGB1 expression level increased by UVB irradiation in keratinocytes, reduce the inflammatory response, and achieve the effect of anti-UVB damage.

[0048] Optionally, the mass ratio of the compound of formula (I) to palmitoyl tripeptide-5 is 25:0.3 to 3.

[0049] Specifically, the mass ratio of the compound shown in formula (I) to palmitoyl tripeptide-5 can be 25:0.3 or 25:0.4 or 25:0.5 or 25:0.6 or 25:0.7 or 25:0.8 or 25:0.9 or 25:1 or 25:1.1 or 25:1.2 or 25:1.3 or 25:1.4 or 25:1.5 or 25:1.6 or 25:1.7 or 25:1.8 or 25:1.9 or 25:2 or 25:2.1 or 25:2.2 or 25:2.3 or 25:2.4 or 25:2.5 or 25:2.6 or 25:2.7 or 25:2.8 or 25:2.9 or 25:3, etc.

[0050] In some embodiments, the composition is selected from a second composition, wherein the first compound is selected from the compounds represented by formula (I), and the second compound is selected from acetyl dipeptide-1 cetyl ester; the first compound and the second compound can synergistically reduce the HMGB1 expression level increased in keratinocytes due to UVB irradiation, reduce the inflammatory response, and achieve the effect of resisting UVB damage.

[0051] Optionally, the mass ratio of the compound of formula (I) to acetyl dipeptide-1 cetyl ester is 25:0.5 to 4.

[0052] Specifically, the mass ratio of the compound of formula (I) to acetyl dipeptide-1 cetyl ester can be 25:0.5 or 25:0.6 or 25:0.7 or 25:0.8 or 25:0.9 or 25:1 or 25:1.1 or 25:1.2 or 25:1.3 or 25:1.4 or 25:1.5 or 25:1.6 or 25:1.7 or 25:1.8 or 25:1.9 or 25:2 or 25:2.1 or 25:2.2 or 25:2.3 or 25:2.4 or 25:2.5 or 25:2.6 or 25:2.7 or 25:2.8 or 25:2.9 or 25:3 or 25:3.1 or 25:3.2 or 25:3.3 or 25:3.4 or 25:3.5 or 25:3.6 or 25:3.7 or 25:3.8 or 25:3.9 or 25:4, etc.

[0053] In some embodiments, the composition is selected from a third composition, wherein the first compound is selected from the compounds represented by formula (I), and the second compound is selected from acetyl tripeptide-30 citrulline; the first compound and the second compound can synergistically reduce the HMGB1 expression level increased in keratinocytes due to UVB irradiation, reduce the inflammatory response, and achieve the effect of resisting UVB damage.

[0054] Optionally, the mass ratio of the compound of formula (I) to acetyl tripeptide-30 citrulline is 25:0.5 to 3;

[0055] Specifically, the mass ratio of the compound of formula (I) to acetyl tripeptide-30 citrulline can be 25:0.5 or 25:0.6 or 25:0.7 or 25:0.8 or 25:0.9 or 25:1 or 25:1.1 or 25:1.2 or 25:1.3 or 25:1.4 or 25:1.5 or 25:1.6 or 25:1.7 or 25:1.8 or 25:1.9 or 25:2 or 25:2.1 or 25:2.2 or 25:2.3 or 25:2.4 or 25:2.5 or 25:2.6 or 25:2.7 or 25:2.8 or 25:2.9 or 25:3, etc.

[0056] In some embodiments, the composition is selected from a fourth composition, wherein the first compound is selected from the compounds represented by formula (I), and the second compound is selected from palmitoyl pentapeptide-4; the first compound and the second compound can synergistically reduce the HMGB1 expression level increased by keratinocytes due to UVB irradiation, reduce the inflammatory response, and achieve the effect of anti-UVB damage.

[0057] Optionally, the mass ratio of the compound of formula (I) to palmitoyl pentapeptide-4 is 25:0.05 to 0.5;

[0058] Specifically, the mass ratio of the compound of formula (I) to palmitoyl pentapeptide-4 can be 25:0.05 or 25:0.1 or 25:0.15 or 25:0.2 or 25:0.25 or 25:0.3 or 25:0.35 or 25:0.4 or 25:0.45 or 25:0.5, etc.

[0059] SLC7A11 (Solute Carrier Family 7 Member 11) is a cystine transporter that is highly specific for cystine and glutamate. Its function is to participate in the extracellular uptake of cystine and the release of glutamate, promote the synthesis of glutathione, protect cells from oxidative stress damage, maintain the cellular redox balance, and thus prevent cell death caused by lipid peroxidation. UVB irradiation can lead to a decrease in the expression level of SLC7A11.

[0060] In some embodiments, when the composition is selected from any one of a fifth composition, a sixth composition, a seventh composition, and an eighth composition, it can increase the SLC7A11 expression level decreased by keratinocytes due to UVB irradiation, reduce the inflammatory response, and achieve the effect of anti-UVB damage.

[0061] In some embodiments, the composition is selected from a fifth composition, wherein the first compound is selected from the compounds represented by formula (II), and the second compound is selected from palmitoyl tripeptide-5; the first compound and the second compound can synergistically increase the SLC7A11 expression level decreased by keratinocytes due to UVB irradiation, reduce the inflammatory response, and achieve the effect of anti-UVB damage.

[0062] Optionally, the mass ratio of the compound of formula (II) to palmitoyl tripeptide-5 is 25:0.3 to 3;

[0063] Specifically, the mass ratio of the compound of formula (II) to palmitoyl tripeptide-5 can be 25:0.3 or 25:0.4 or 25:0.5 or 25:0.6 or 25:0.7 or 25:0.8 or 25:0.9 or 25:1 or 25:1.1 or 25:1.2 or 25:1.3 or 25:1.4 or 25:1.5 or 25:1.6 or 25:1.7 or 25:1.8 or 25:1.9 or 25:2 or 25:2.1 or 25:2.2 or 25:2.3 or 25:2.4 or 25:2.5 or 25:2.6 or 25:2.7 or 25:2.8 or 25:2.9 or 25:3, etc.

[0064] In some embodiments, the composition is selected from the sixth composition, wherein the first compound is selected from the compounds represented by formula (II), and the second compound is selected from acetyl dipeptide-1 cetyl ester; the first compound and the second compound can synergistically increase the expression level of SLC7A11 in keratinocytes decreased by UVB irradiation, reduce the inflammatory response, and achieve the effect of anti-UVB damage.

[0065] Optionally, the mass ratio of the compound of formula (II) to acetyl dipeptide-1 cetyl ester is 25:0.5 to 4;

[0066] Specifically, the mass ratio of the compound of formula (II) to acetyl dipeptide-1 cetyl ester can be 25:0.5 or 25:0.6 or 25:0.7 or 25:0.8 or 25:0.9 or 25:1 or 25:1.1 or 25:1.2 or 25:1.3 or 25:1.4 or 25:1.5 or 25:1.6 or 25:1.7 or 25:1.8 or 25:1.9 or 25:2 or 25:2.1 or 25:2.2 or 25:2.3 or 25:2.4 or 25:2.5 or 25:2.6 or 25:2.7 or 25:2.8 or 25:2.9 or 25:3 or 25:3.1 or 25:3.2 or 25:3.3 or 25:3.4 or 25:3.5 or 25:3.6 or 25:3.7 or 25:3.8 or 25:3.9 or 25:4, etc.

[0067] In some embodiments, the composition is selected from the seventh composition, wherein the first compound is selected from the compounds represented by formula (II), and the second compound is selected from acetyl tripeptide-30 citrulline; the first compound and the second compound can synergistically increase the expression level of SLC7A11 in keratinocytes decreased by UVB irradiation, reduce the inflammatory response, and achieve the effect of anti-UVB damage.

[0068] Optionally, the mass ratio of the compound of formula (II) to acetyl tripeptide-30 citrulline is 25:0.5 to 3;

[0069] Specifically, the mass ratio of the compound of formula (II) to acetyl tripeptide-30 citrulline can be 25:0.5 or 25:0.6 or 25:0.7 or 25:0.8 or 25:0.9 or 25:1 or 25:1.1 or 25:1.2 or 25:1.3 or 25:1.4 or 25:1.5 or 25:1.6 or 25:1.7 or 25:1.8 or 25:1.9 or 25:2 or 25:2.1 or 25:2.2 or 25:2.3 or 25:2.4 or 25:2.5 or 25:2.6 or 25:2.7 or 25:2.8 or 25:2.9 or 25:3, etc.

[0070] In some embodiments, the composition is selected from the eighth composition, wherein the first compound is selected from the compounds represented by formula (II), and the second compound is selected from palmitoyl pentapeptide-4; the first compound and the second compound can synergistically increase the expression level of SLC7A11 decreased by UVB irradiation in keratinocytes, reduce the inflammatory response, and achieve the effect of anti-UVB damage.

[0071] Optionally, the mass ratio of the compound of formula (II) to palmitoyl pentapeptide-4 is 25:0.05 to 0.5;

[0072] Specifically, the mass ratio of the compound of formula (II) to palmitoyl pentapeptide-4 can be 25:0.05 or 25:0.1 or 25:0.15 or 25:0.2 or 25:0.25 or 25:0.3 or 25:0.35 or 25:0.4 or 25:0.45 or 25:0.5, etc.

[0073] It should be noted that palmitoyl tripeptide-5, acetyl dipeptide-1 cetyl ester, acetyl tripeptide-30 citrulline, and palmitoyl pentapeptide-4 can be obtained by direct purchase or synthesized by methods known to those skilled in the art.

[0074] It can be understood that in some embodiments, the composition is a skin care composition and can be used for skin care.

[0075] In some embodiments, the composition can be in the form of creams such as milk, paste, cream, honey, fat, milk, lotion, milk, milk lotion, etc., or in the form of liquids such as lotion, liquid, water, oil, oil-water separation, etc., or in the form of gels such as jelly, glue, etc., powders such as loose powder, granules, etc., or in the form of blocks such as block powder, large solid, etc., or in the form of mud-like solid, or in the form of wax-based materials with wax as the main base material, etc., or in the form of lyophilized products such as lyophilized powder, lyophilized tablets, etc., or in the form of sprays without propellants, etc., or in the form of aerosols with propellants, etc., or in the form of substrates such as patches, films, etc. for use in combination with cosmetics.

[0076] In some embodiments, the composition can be topically applied to hair, body hair, torso, head, face, eyes, lips, hands, feet, whole body skin, fingers (toes), fingernails (toenails).

[0077] In some embodiments, the composition can comprise at least one cosmetically acceptable adjuvant. The adjuvant is selected from one or more of surfactants and / or emulsifiers, preservatives, buffers, chelating agents, denaturing agents, sunscreen agents, pH regulators, reducing agents and stabilizers, thickeners, gelling agents, film-forming polymers, fillers, matting agents, brightening agents, pigments, dyes, fragrances, and mixtures thereof.

[0078] In some embodiments, the composition can comprise at least one cosmetically acceptable active ingredient. The active ingredient is selected from one or more of caffeine, caffeic acid, cyclic peptides, vitamin A and its derivatives, retinol, vitamin C and its derivatives, vitamin E and its derivatives, arbutin, cinnamic acid and its derivatives, ferulic acid, ergothioneine, ectoine, glabridin, bisabolol, ceramides, phenylethyl resorcinol, soluble collagen, adenosine, 4-butylresorcinol, hydrolyzed collagen, inositol, carbohydrate isomers, fibronectin, astaxanthin, asiaticoside, rhamnose, resveratrol, amino acids, hydroxypropyltetrahydropyrantriol, fermentates, sodium hyaluronate, niacinamide, panthenol, plant extracts.

[0079] In some embodiments, the composition can further comprise a solvent, and the solvent can be selected from one or more of dibutyl adipate, isononyl isononanoate, pentaerythritol tetra(ethylhexanoate), caprylic / capric triglyceride, cetyl alcohol ethylhexanoate, diisostearyl malate, octyldodecanol.

[0080] In some embodiments, the composition can further comprise a cosmetically acceptable adjuvant.

[0081] In some embodiments, the mass concentration (mass fraction) of the first compound and the second compound can be 0.0001 - 10% of the total weight of the composition.

[0082] It should be noted that the compound of formula (I) can be obtained by direct purchase or by synthesis through the methods shown in the following steps S11 to S13:

[0083] Step S11: Add 466 mg of ferulic acid (3-methoxy-4-hydroxycinnamic acid) to a 50 mL round-bottom flask, dissolve it with 10 mL of dichloromethane, then add 1.4 mL of triethylamine. The resulting reaction solution is stirred magnetically and cooled to 0 - 5 °C in an ice-water bath. Slowly add 900 mg of tert-butyldimethylchlorosilane and stir at room temperature for 4 hours. After the reaction is completed, add 25 mL of ice water to quench the reaction, extract the aqueous layer with dichloromethane (25 mL × 3), combine the organic layers, add anhydrous sodium sulfate to dry the organic layer, filter, and concentrate under vacuum to obtain the crude product. Dissolve the crude product with 20 mL of tetrahydrofuran and 2 mL of water, add 200 mg of anhydrous potassium carbonate, and stir at room temperature for 6 hours. After the reaction is completed, add 25 mL of water and extract the aqueous layer with ethyl acetate (25 mL × 3), combine the organic layers, concentrate under vacuum, and recrystallize with petroleum ether to obtain the first intermediate.

[0084] Step S12: Add 308 mg of the first intermediate, 343 mg of retinol, 288 mg of EDCI, and 12 mg of DMAP to a 50 mL brown round-bottom flask, dissolve them with 5 mL of tetrahydrofuran, and finally add 270 μL of TEA. Stir at room temperature for 12 hours. After the reaction is completed, concentrate the reaction solution under vacuum, add 25 mL of water, extract the aqueous layer with ethyl acetate (25 mL × 3), combine the organic layers, add anhydrous sodium sulfate to dry the organic layer, filter, and concentrate under vacuum to obtain the crude product. Use silica gel column chromatography (petroleum ether:ethyl acetate = 20:1 as the eluent) to obtain the second intermediate.

[0085] Step S13: Add 384 mg of the second intermediate to a 50 mL brown round-bottom flask, dissolve it with 8 mL of tetrahydrofuran, cool it to 0 - 5 °C in an ice-water bath, and slowly dropwise add 600 μL of tetrabutylammonium fluoride. Stir in the ice bath for 10 minutes. Concentrate under vacuum to obtain the crude product. Use silica gel column chromatography (petroleum ether:ethyl acetate = 5:1 as the eluent) to obtain the compound of formula (I).

[0086] The mass spectrometry data of the compound of formula (I) is as Figure 2 shown.

[0087] The NMR of the compound of formula (I) is as Figure 1 shown, and the data is as follows:

[0088] 1 H NMR(500MHz,CDCl 3)δ 7.62 (d, J = 15.9 Hz, 1H), 7.07 (dd, J = 8.3, 2.0 Hz, 1H), 7.02 (d, J = 1.9 Hz, 1H), 6.91 (d, J = 8.2 Hz, 1H), 6.65 (dd, J = 15.1, 11.2 Hz, 1H), 6.30 (d, J = 15.9 Hz, 2H), 6.22–6.06 (m, 3H), 5.90 (s, 1H), 5.69 (t, J = 7.2 Hz, 1H), 4.86 (d, J = 7.2 Hz, 2H), 3.92 (s, 3H), 2.01 (t, J = 6.3 Hz, 2H), 1.96 (s, 3H), 1.93 (s, 3H), 1.71 (s, 3H), 1.63–1.57 (m, 2H), 1.49–1.44 (m, 2H), 1.02 (s, 6H).

[0089] The compound of formula (II) can be obtained by direct purchase or by synthesis through the method shown in the following steps S21 to S27:

[0090] Step S21: Mix 3-(benzo[d][1,3]dioxol-5-yl)acrylic acid, bakuchiol, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, 4-dimethylaminopyridine, triethylamine and tetrahydrofuran, and stir evenly at room temperature to obtain a mixture.

[0091] In practice, 4.5 g (22.6 mmol, 1.5 equiv) of 3-(benzo[d][1,3]dioxol-5-yl)acrylic acid, 4.5 g (15 mmol, 1 equiv) of bakuchiol, 5.76 g (30 mmol, 2 equiv) of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, 180 mg (1.5 mmol, 0.1 equiv) of 4-dimethylaminopyridine, 4.8 mL (37.6 mmol, 2.5 equiv) of triethylamine and 80 mL of tetrahydrofuran can be added to a 200 mL reaction kettle, and stirred at room temperature for 12 hours to obtain a mixture.

[0092] Step S22: Perform a first vacuum concentration on the above mixture to obtain a first concentrate.

[0093] Among them, the above mixture is subjected to vacuum concentration at a temperature of 40 ± 5 °C to obtain a first concentrate.

[0094] Step S23: Extract the target fraction from the above first concentrate dissolved in water with ethyl acetate, and collect the organic layer.

[0095] In practice, first, 200 mL of water is added to the first concentrate to dissolve the first concentrate in water. Then, the target layer of the water layer of the first concentrate after water dissolution is extracted with ethyl acetate (200 mL × 3). Among them, the target layer ≥ 1. Finally, the organic layers are combined.

[0096] Step S24: Perform a second vacuum concentration on the dried organic layer to obtain a second concentrate.

[0097] In practice, first, 10 g of anhydrous sodium sulfate is added to the organic layer to dry and filter the organic layer, obtaining the dried organic layer. Then, under the temperature condition of 40 ± 5 °C, perform a vacuum concentration on the dried organic layer to obtain a second concentrate (crude oil product).

[0098] Step S25: Add petroleum ether to the second concentrate and perform a third vacuum concentration to obtain a first solid.

[0099] In practice, 60 mL of petroleum ether is added to the second concentrate, and under the temperature condition of 40 ± 5 °C, perform a vacuum concentration to obtain a first solid (yellow solid).

[0100] Step S26: Mix the mixed solution with the first solid and then perform slurry filtration to obtain a filter cake.

[0101] Among them, the mixed solution includes: petroleum ether and ethyl acetate, and the volume ratio of petroleum ether to ethyl acetate is 50:1.

[0102] In practice, mix 200 mL of the mixed solution composed of petroleum ether and ethyl acetate with the first solid and perform slurry for 30 minutes, and filter with a Buchner funnel to obtain a filter cake.

[0103] Step S27: Perform vacuum drying on the filter cake to obtain the compound of formula (II).

[0104] In practice, under the temperature condition of 40 ± 5 °C, perform vacuum drying on the filter cake to obtain the compound of formula (II). Specifically, the mass spectrum of the compound of formula (II) is as Figure 4 shown.

[0105] The NMR of the compound of formula (II) is as Figure 3 shown, and the data is as follows:

[0106] 1 H NMR(500MHz,CDCl 3)δ 7.77 (d, J = 15.9 Hz, 1H), 7.39 (d, J = 8.6 Hz, 2H), 7.10 (d, J = 2.0 Hz, 1H), 7.09 (q, J = 2.8, 2.3 Hz, 2H), 7.06 (dd, J = 8.1, 1.7 Hz, 1H), 6.84 (d, J = 8.0 Hz, 1H), 6.44 (d, J = 15.9 Hz, 1H), 6.32 (d, J = 16.2 Hz, 1H), 6.18 (d, J = 16.3 Hz, 1H), 6.03 (s, 2H), 5.89 (dd, J = 17.5, 10.7 Hz, 1H), 5.11 (tt, J = 7.1, 1.4 Hz, 1H), 5.08–4.99 (m, 2H), 1.96 (q, J = 7.5 Hz, 2H), 1.68 (s, 3H), 1.59 (s, 3H), 1.54–1.48 (m, 2H), 1.21 (s, 3H).

[0107] Among them, the nuclear magnetic data was measured by a nuclear magnetic resonance spectrometer (Model: AVANCE III HD 400 MHz, Manufacturer: Bruker Corporation, Switzerland).

[0108] In some embodiments, the wavelength of UVB is 320 nm to 400 nm.

[0109] <Skin care product>

[0110] As can be seen from the foregoing, the composition described in the embodiments of the first aspect can reduce the inflammatory response caused by UVB irradiation in skin cells and has a skin care effect. Therefore, in some embodiments, the composition can be used as a skin care product or further used to prepare a skin care product.

[0111] Therefore, it can be understood that based on the composition described in the embodiments of the first aspect, the embodiments of the present application can further provide a skin care product, which includes:

[0112] A first compound, which is selected from the compounds represented by formula (I) or formula (II); and

[0113] A second compound, which is selected from any one of Palmitoyl Tripeptide-5, Acetyl Dipeptide-1 Cetyl Ester, AcetylTripeptide-30 Citrulline, and Palmitoyl Pentapeptide-4.

[0114] The skin care product provided by the embodiment of the present application includes a first compound and a second compound, and has a UVB damage effect. Specifically, through the synergistic effect generated by the combination of the first compound and the second compound, the inflammatory response of skin cells (keratinocytes) caused by UVB irradiation can be reduced, and the anti-inflammatory effect can be achieved.

[0115] In some embodiments, the skin care product further includes a solvent, and the solvent is a cosmetically acceptable solvent, for example, it can be selected from one or more of dibutyl adipate, isononyl isononanoate, pentaerythritol tetra(ethylhexanoate), triglyceride caprylate / caprate, cetyl alcohol ethylhexanoate, diisostearyl malate, octyldodecanol.

[0116] In some embodiments, the sum of the concentrations of the first compound, the second compound and the solvent is 0.0001-10% of the total weight of the skin care product.

[0117] In some embodiments, the skin care product includes: a cosmetically acceptable adjuvant.

[0118] <Use>

[0119] In some embodiments, the embodiment of the present application provides a use of the composition having the function of resisting UVB damage described in the first aspect in the preparation of a skin care product. By reducing HMGB1 or increasing the expression of SLC7A11, the effect of resisting UVB damage can be achieved, and the skin care effect can be realized.

[0120] In some embodiments, the embodiment of the present application provides a use of the composition described in the first aspect in the preparation of an anti-UVB damage preparation. By reducing HMGB1 or increasing the expression of SLC7A11, the effect of resisting UVB damage can be achieved.

[0121] In some embodiments, the embodiment of the present application provides a use of the composition described in the first aspect in the preparation of a DNA damage inhibitor. By reducing HMGB1 or increasing the expression of SLC7A11, the effect of resisting DNA damage can be achieved, and further the effect of resisting UVB damage can be realized.

[0122] In some embodiments, the embodiment of the present application provides a use of the composition described in the first aspect in the preparation of an HMGB1 expression inhibitor, wherein the composition is selected from any one of the first composition, the second composition, the third composition, and the fourth composition. By reducing the expression of HMGB1, the effect of resisting UVB damage can be achieved.

[0123] In some embodiments, the embodiments of the present application provide the use of the composition described in the first aspect in the preparation of an SLC7A11 expression promoter, wherein the composition is selected from any one of the fifth composition, the sixth composition, the seventh composition, and the eighth composition. By increasing the expression of SLC7A11, the effect of resisting UVB damage can be achieved.

[0124] <Experiment>

[0125] Experimental cells

[0126] Keratinocyte HaCaT

[0127] Experimental reagents

[0128] Compound of formula (I).

[0129] Compound of formula (II).

[0130] Palmitoyl tripeptide-5 (from GenScript Biotech Corporation).

[0131] Acetyl dipeptide-1 cetyl ester (from GenScript Biotech Corporation).

[0132] Acetyl tripeptide-30 citrulline (from GenScript Biotech Corporation).

[0133] Palmitoyl pentapeptide-4 (from GenScript Biotech Corporation).

[0134] DMEM (dulbecco's modified eagle medium): It is a basal medium, purchased from Gibco biological medium of Thermo Fisher Scientific (China) Co., Ltd., and the product catalog number is C11995500BT.

[0135] Fetal bovine serum (FBS): Purchased from Gibco brand fetal bovine serum of Thermo Fisher Scientific (China) Co., Ltd., and the product catalog number is 10091148.

[0136] Penicillin / streptomycin: Purchased from Gibco brand penicillin / streptomycin of Thermo Fisher Scientific (China) Co., Ltd., the catalog number is 25200114, penicillin / streptomycin solution (10,000 U / mL), which includes penicillin and streptomycin, and the concentrations are 10,000 U / mL respectively.

[0137] Phosphate Buffered Saline (PBS): with a pH of 7.4, it is a balanced salt solution suitable for various cell culture applications, such as washing cells before dissociation, transporting cells or tissues, diluting cells for counting, and preparing reagents; PBS of Gibco brand purchased from Thermo Fisher Scientific (China) Co., Ltd.

[0138] RNA extraction kit. Specifically, TransZol Up Plus RNA Kit (Transgen Biotech) can be selected. It is purchased from Beijing TransGen Biotech Co., Ltd. and is suitable for extracting total RNA from cells and tissues. After lysing the sample with TransZolUp and adding RNA Extraction Agent, the solution is divided into a colorless aqueous phase and a pink organic phase, and the RNA is in the aqueous phase; the RNA in the aqueous phase is specifically adsorbed by a silica membrane centrifugal column. The RNA extraction kit specifically includes the following components: 100 ml of TransZolUp, 20 ml of RNA Extraction Agent, 110 ml of Clean Buffer 9 (CB9), 24 ml of Wash Buffer 9 (WB9), 40 ml of RNase-free Water, 100 each of RNase-free Tubes (1.5 ml), and 100 each of RNA SpinColumns with Collection Tubes.

[0139] Reverse transcription kit using M-MLV reverse transcriptase. Select Evo M-MLV Reverse Transcription Premix Kit (containing reagent for removing gDNA, for qPCR) Ver.2 (Agbio, AG11728), which contains 5X Evo M-MLV RT Reaction Mix, and the cDNA product can be directly used for qPCR detection. Evo M-MLV Reverse Transcription Premix Kit (containing reagent for removing gDNA, for qPCR) Ver.2 contains all components required for the reverse transcription reaction.

[0140] 2× Premixed solution for real-time quantitative PCR amplification (English name: 2×qPCR SYBR Green MasterMix, abbreviated as SYBR Mix). This Mix contains hot-start DNA polymerase ( DNA Polymerase), SYBRGreen I, deoxynucleoside triphosphates (dNTPs), and magnesium ions (Mg 2+ ). Specifically, qPCR SYBR Green Master Mix can be selected qPCR SYBR Green Master Mix (No Rox), which can be purchased from Yeasen with the product number 11202ES.

[0141] Experimental equipment

[0142] CO 2 Incubator (Thermo, 150I).

[0143] Laminar flow hood (Suzhou Jing'an Antai, SW-CJ-1F).

[0144] Micro-spectrophotometer (Thermo Scientific NanoDrop).

[0145] ProFlex TM PCR instrument (Applied Biosystems SimpliAmp PCR Thermal Cycler).

[0146] QPCR instrument (Applied Biosystems QuantStudio 1).

[0147] UV crosslinker (UVB crosslinker, Luyor UCL-3500).

[0148] High-speed refrigerated centrifuge (Eppendorf Centrifuge 5418R).

[0149] Experimental samples and preparation :

[0150] 1. Related solutions for preparing samples

[0151] Basal medium solution: DMEM medium solution containing FBS, penicillin / streptomycin, specifically DMEM medium solution containing 10% FBS and 1% penicillin / streptomycin; among them, the mass fraction of FBS is 10%, and the mass fraction of penicillin / streptomycin is 1%; this basal medium solution can be prepared by mixing FBS, penicillin / streptomycin and DMEM medium.

[0152] Mother liquor containing the compound of formula (I): Mix the compound powder of formula (I) into dimethyl sulfoxide (DMSO) to form a mother liquor, and the concentration can be adjusted as needed.

[0153] Mother liquor containing the compound of formula (II): Mix the compound powder of formula (II) into DMSO to form a mother liquor, and the concentration can be adjusted as needed.

[0154] Palmitoyl Tripeptide-5 Stock Solution: Mix palmitoyl tripeptide-5 powder into DMSO to form the palmitoyl tripeptide-5 stock solution, and the concentration can be adjusted as needed.

[0155] Palmitoyl Tripeptide-5 Stock Solution: Mix acetyl dipeptide-1 powder into DMSO to form the palmitoyl tripeptide-5 stock solution, and the concentration can be adjusted as needed.

[0156] Acetyl Tripeptide-30 Citrulline Stock Solution: Mix acetyl tripeptide-30 citrulline powder into water to form the acetyl tripeptide-30 citrulline stock solution, and the concentration can be adjusted as needed.

[0157] Palmitoyl Pentapeptide-4 Stock Solution: Mix palmitoyl pentapeptide-4 powder into DMSO to form the palmitoyl pentapeptide-4 stock solution, and the concentration can be adjusted as needed.

[0158] 2. Samples

[0159] Blank Control Group Sample: Select the basal medium solution as the blank control group sample.

[0160] UVB Control Group Sample: Select the basal medium solution as the UVB control group sample.

[0161] Sample 1-1: A DMEM medium solution containing the compound of formula (I) at a concentration of 12.5 μg / mL. Specifically, dilute the stock solution containing the compound of formula (I) with the basal medium solution to a concentration of 12.5 μg / mL of the compound of formula (I), and then this sample can be obtained.

[0162] Sample 1-2: A DMEM medium solution containing palmitoyl tripeptide-5 at a concentration of 0.15 μg / mL. Specifically, dilute the palmitoyl tripeptide-5 stock solution with the basal medium solution to a concentration of 0.15 μg / mL of palmitoyl tripeptide-5, and then this sample can be obtained.

[0163] Sample 1-3: A DMEM medium solution containing palmitoyl tripeptide-5 at a concentration of 1.5 μg / mL. Specifically, dilute the palmitoyl tripeptide-5 stock solution with the basal medium solution to a concentration of 12.5 μg / mL of palmitoyl tripeptide-5, and then this sample can be obtained.

[0164] Sample 1-4: A DMEM medium solution containing the compound of formula (I) at a concentration of 12.5 μg / mL and palmitoyl tripeptide-5 at a concentration of 0.15 μg / mL. Specifically, mix and dilute the basal medium solution with the stock solution containing the compound of formula (I) and the palmitoyl tripeptide-5 stock solution until the concentration of the compound of formula (I) is 12.5 μg / mL and the concentration of palmitoyl tripeptide-5 is 0.15 μg / mL, and then this sample can be obtained.

[0165] Samples 1-5: DMEM medium solutions containing the compound of formula (I) at a concentration of 12.5 μg / mL and palmitoyl tripeptide-5 at a concentration of 1.5 μg / mL. Specifically, a basal medium solution is mixed with a stock solution containing the compound of formula (I) and a stock solution of palmitoyl tripeptide-5 for dilution until the concentration of the compound of formula (I) is 12.5 μg / mL and the concentration of palmitoyl tripeptide-5 is 1.5 μg / mL, and then this sample can be obtained.

[0166] Sample 2-1: DMEM medium solution containing the compound of formula (I) at a concentration of 12.5 μg / mL. Specifically, a stock solution containing the compound of formula (I) is diluted with a basal medium solution until the concentration of the compound of formula (I) is 12.5 μg / mL, and then this sample can be obtained.

[0167] Sample 2-2: DMEM medium solution containing acetyl dipeptide-1 cetyl ester at a concentration of 0.25 μg / mL. Specifically, a stock solution of acetyl dipeptide-1 cetyl ester is diluted with a basal medium solution until the concentration of acetyl dipeptide-1 cetyl ester is 0.25 μg / mL, and then this sample can be obtained.

[0168] Sample 2-3: DMEM medium solution containing acetyl dipeptide-1 cetyl ester at a concentration of 2.0 μg / mL. Specifically, a stock solution of acetyl dipeptide-1 cetyl ester is diluted with a basal medium solution until the concentration of acetyl dipeptide-1 cetyl ester is 2.0 μg / mL, and then this sample can be obtained.

[0169] Sample 2-4: DMEM medium solution containing the compound of formula (I) at a concentration of 12.5 μg / mL and acetyl dipeptide-1 cetyl ester at a concentration of 0.25 μg / mL. Specifically, a basal medium solution is mixed with a stock solution containing the compound of formula (I) and a stock solution of acetyl dipeptide-1 cetyl ester for dilution until the concentration of the compound of formula (I) is 12.5 μg / mL and the concentration of acetyl dipeptide-1 cetyl ester is 0.25 μg / mL, and then this sample can be obtained.

[0170] Sample 2-5: DMEM medium solution containing the compound of formula (I) at a concentration of 12.5 μg / mL and acetyl dipeptide-1 cetyl ester at a concentration of 2.0 μg / mL. Specifically, a basal medium solution is mixed with a stock solution containing the compound of formula (I) and a stock solution of acetyl dipeptide-1 cetyl ester for dilution until the concentration of the compound of formula (I) is 12.5 μg / mL and the concentration of acetyl dipeptide-1 cetyl ester is 2.0 μg / mL, and then this sample can be obtained.

[0171] Sample 3-1: A DMEM medium solution containing the compound of formula (I) at a concentration of 12.5 μg / mL. Specifically, the mother liquor containing the compound of formula (I) is diluted with the basal medium solution to a concentration of 12.5 μg / mL of the compound of formula (I), and then this sample can be obtained.

[0172] Sample 3-2: A DMEM medium solution containing acetyl tripeptide-30 citrulline at a concentration of 0.25 μg / mL. Specifically, the mother liquor of acetyl tripeptide-30 citrulline is diluted with the basal medium solution to a concentration of 0.15 μg / mL of acetyl tripeptide-30 citrulline, and then this sample can be obtained.

[0173] Sample 3-3: A DMEM medium solution containing acetyl tripeptide-30 citrulline at a concentration of 1.5 μg / mL. Specifically, the mother liquor of acetyl tripeptide-30 citrulline is diluted with the basal medium solution to a concentration of 1.5 μg / mL of acetyl tripeptide-30 citrulline, and then this sample can be obtained.

[0174] Sample 3-4: A DMEM medium solution containing the compound of formula (I) at a concentration of 12.5 μg / mL and acetyl tripeptide-30 citrulline at a concentration of 0.15 μg / mL. Specifically, the basal medium solution is mixed with the mother liquor containing the compound of formula (I) and the mother liquor of acetyl tripeptide-30 citrulline for dilution until the concentration of the compound of formula (I) is 12.5 μg / mL and the concentration of acetyl tripeptide-30 citrulline is 0.25 μg / mL, and then this sample can be obtained.

[0175] Sample 3-5: A DMEM medium solution containing the compound of formula (I) at a concentration of 12.5 μg / mL and acetyl tripeptide-30 citrulline at a concentration of 1.5 μg / mL. Specifically, the basal medium solution is mixed with the mother liquor containing the compound of formula (I) and the mother liquor of acetyl tripeptide-30 citrulline for dilution until the concentration of the compound of formula (I) is 12.5 μg / mL and the concentration of acetyl tripeptide-30 citrulline is 1.5 μg / mL, and then this sample can be obtained.

[0176] Sample 4-1: A DMEM medium solution containing the compound of formula (I) at a concentration of 12.5 μg / mL. Specifically, the mother liquor containing the compound of formula (I) is diluted with the basal medium solution to a concentration of 12.5 μg / mL of the compound of formula (I), and then this sample can be obtained.

[0177] Sample 4-2: A DMEM medium solution containing palmitoyl pentapeptide-4 at a concentration of 0.025 μg / mL. Specifically, the mother liquor containing palmitoyl pentapeptide-4 is diluted with the basal medium solution to a concentration of 0.025 μg / mL of palmitoyl pentapeptide-4, and then this sample can be obtained.

[0178] Sample 4-3: A DMEM medium solution containing palmitoyl pentapeptide-4 at a concentration of 0.25 μg / mL. Specifically, the mother liquor containing palmitoyl pentapeptide-4 is diluted with the basal medium solution to a concentration of 0.25 μg / mL of palmitoyl pentapeptide-4, and then this sample can be obtained.

[0179] Sample 4-4: A DMEM medium solution containing the compound of formula (I) at a concentration of 12.5 μg / mL and palmitoyl pentapeptide-4 at a concentration of 0.025 μg / mL. Specifically, the basal medium solution is mixed with the mother liquor containing the compound of formula (I) and the mother liquor of acetyl tripeptide-30 citrulline for dilution until the concentration of the compound of formula (I) is 12.5 μg / mL and the concentration of palmitoyl pentapeptide-4 is 0.025 μg / mL, and then this sample can be obtained.

[0180] Sample 4-5: A DMEM medium solution containing the compound of formula (I) at a concentration of 12.5 μg / mL and palmitoyl pentapeptide-4 at a concentration of 0.25 μg / mL. Specifically, the basal medium solution is mixed with the mother liquor containing the compound of formula (I) and the mother liquor of acetyl tripeptide-30 citrulline for dilution until the concentration of the compound of formula (I) is 12.5 μg / mL and the concentration of palmitoyl pentapeptide-4 is 0.25 μg / mL, and then this sample can be obtained.

[0181] Sample 5-1: A DMEM medium solution containing the compound of formula (II) at a concentration of 150 μg / mL. Specifically, the mother liquor containing the compound of formula (II) is diluted with the basal medium solution to a concentration of 150 μg / mL of the compound of formula (II), and then this sample can be obtained.

[0182] Sample 5-2: A DMEM medium solution containing palmitoyl tripeptide-5 at a concentration of 1.8 μg / mL. Specifically, the mother liquor of palmitoyl tripeptide-5 is diluted with the basal medium solution to a concentration of 1.8 μg / mL of palmitoyl tripeptide-5, and then this sample can be obtained.

[0183] Sample 5-3: A DMEM medium solution containing palmitoyl tripeptide-5 at a concentration of 18 μg / mL. Specifically, the mother liquor of palmitoyl tripeptide-5 is diluted with the basal medium solution to a concentration of 18 μg / mL of palmitoyl tripeptide-5, and then this sample can be obtained.

[0184] Sample 5-4: A DMEM medium solution containing a compound of formula (II) at a concentration of 150 μg / mL and palmitoyl tripeptide-5 at a concentration of 1.8 μg / mL. Specifically, it is obtained by mixing a basal medium solution with a stock solution containing the compound of formula (II) and a stock solution of palmitoyl tripeptide-5 for dilution until the concentration of the compound of formula (II) is 150 μg / mL and the concentration of palmitoyl tripeptide-5 is 1.8 μg / mL.

[0185] Sample 5-5: A DMEM medium solution containing a compound of formula (II) at a concentration of 150 μg / mL and palmitoyl tripeptide-5 at a concentration of 18 μg / mL. Specifically, it is obtained by mixing a basal medium solution with a stock solution containing the compound of formula (II) and a stock solution of palmitoyl tripeptide-5 for dilution until the concentration of the compound of formula (II) is 150 μg / mL and the concentration of palmitoyl tripeptide-5 is 18 μg / mL.

[0186] Sample 6-1: A DMEM medium solution containing a compound of formula (II) at a concentration of 150 μg / mL. Specifically, it is obtained by diluting a stock solution containing the compound of formula (II) with a basal medium solution until the concentration of the compound of formula (II) is 150 μg / mL.

[0187] Sample 6-2: A DMEM medium solution containing acetyl dipeptide-1 cetyl ester at a concentration of 3 μg / mL. Specifically, it is obtained by diluting a stock solution of acetyl dipeptide-1 cetyl ester with a basal medium solution until the concentration of acetyl dipeptide-1 cetyl ester is 3 μg / mL.

[0188] Sample 6-3: A DMEM medium solution containing acetyl dipeptide-1 cetyl ester at a concentration of 24 μg / mL. Specifically, it is obtained by diluting a stock solution of acetyl dipeptide-1 cetyl ester with a basal medium solution until the concentration of acetyl dipeptide-1 cetyl ester is 24 μg / mL.

[0189] Sample 6-4: A DMEM medium solution containing a compound of formula (II) at a concentration of 150 μg / mL and acetyl dipeptide-1 cetyl ester at a concentration of 3 μg / mL. Specifically, it is obtained by mixing a basal medium solution with a stock solution containing the compound of formula (II) and a stock solution of acetyl dipeptide-1 cetyl ester for dilution until the concentration of the compound of formula (II) is 150 μg / mL and the concentration of acetyl dipeptide-1 cetyl ester is 3 μg / mL.

[0190] Sample 6-5: A DMEM medium solution containing a compound of formula (II) at a concentration of 150 μg / mL and acetyl dipeptide-1 cetyl ester at a concentration of 24 μg / mL. Specifically, the basal medium solution is mixed with the mother liquor containing the compound of formula (II) and the mother liquor of acetyl dipeptide-1 cetyl ester for dilution until the concentration of the compound of formula (II) is 150 μg / mL and the concentration of acetyl dipeptide-1 cetyl ester is 24 μg / mL, and then this sample can be obtained.

[0191] Sample 7-1: A DMEM medium solution containing a compound of formula (II) at a concentration of 150 μg / mL. Specifically, the mother liquor containing the compound of formula (II) is diluted with the basal medium solution until the concentration of the compound of formula (II) is 150 μg / mL, and then this sample can be obtained.

[0192] Sample 7-2: A DMEM medium solution containing acetyl tripeptide-30 citrulline at a concentration of 3 μg / mL. Specifically, the mother liquor of acetyl tripeptide-30 citrulline is diluted with the basal medium solution until the concentration of acetyl tripeptide-30 citrulline is 3 μg / mL, and then this sample can be obtained.

[0193] Sample 7-3: A DMEM medium solution containing acetyl tripeptide-30 citrulline at a concentration of 18 μg / mL. Specifically, the mother liquor of acetyl tripeptide-30 citrulline is diluted with the basal medium solution until the concentration of acetyl tripeptide-30 citrulline is 18 μg / mL, and then this sample can be obtained.

[0194] Sample 7-4: A DMEM medium solution containing a compound of formula (II) at a concentration of 150 μg / mL and acetyl tripeptide-30 citrulline at a concentration of 3 μg / mL. Specifically, the basal medium solution is mixed with the mother liquor containing the compound of formula (II) and the mother liquor of acetyl tripeptide-30 citrulline for dilution until the concentration of the compound of formula (II) is 150 μg / mL and the concentration of acetyl tripeptide-30 citrulline is 3 μg / mL, and then this sample can be obtained.

[0195] Sample 7-5: A DMEM medium solution containing a compound of formula (II) at a concentration of 150 μg / mL and acetyl tripeptide-30 citrulline at a concentration of 18 μg / mL. Specifically, the basal medium solution is mixed with the mother liquor containing the compound of formula (II) and the mother liquor of acetyl tripeptide-30 citrulline for dilution until the concentration of the compound of formula (II) is 150 μg / mL and the concentration of acetyl tripeptide-30 citrulline is 18 μg / mL, and then this sample can be obtained.

[0196] Sample 8-1: A DMEM culture medium solution containing the compound of formula (II) at a concentration of 150 μg / mL. Specifically, the mother liquor containing the compound of formula (II) is diluted with the basal culture medium solution to a concentration of 150 μg / mL of the compound of formula (II), and then this sample can be obtained.

[0197] Sample 8-2: A DMEM culture medium solution containing palmitoyl pentapeptide-4 at a concentration of 0.3 μg / mL. Specifically, the mother liquor containing palmitoyl pentapeptide-4 is diluted with the basal culture medium solution to a concentration of 0.3 μg / mL of palmitoyl pentapeptide-4, and then this sample can be obtained.

[0198] Sample 8-3: A DMEM culture medium solution containing 3 μg / mL of palmitoyl pentapeptide-4, 10% FBS, and 1% penicillin / streptomycin. Specifically, the mother liquor containing palmitoyl pentapeptide-4 is diluted with the basal culture medium solution to a concentration of 3 μg / mL of palmitoyl pentapeptide-4, and then this sample can be obtained.

[0199] Sample 8-4: A DMEM culture medium solution containing 150 μg / mL of the compound of formula (II) and 0.3 μg / mL of palmitoyl pentapeptide-4. Specifically, the basal culture medium solution is mixed with the mother liquor containing the compound of formula (II) and the mother liquor containing palmitoyl pentapeptide-4 for dilution until the concentration of the compound of formula (II) is 150 μg / mL and the concentration of palmitoyl pentapeptide-4 is 0.3 μg / mL, and then this sample can be obtained.

[0200] Sample 8-5: A DMEM culture medium solution containing 150 μg / mL of the compound of formula (II) and 3 μg / mL of palmitoyl pentapeptide-4. Specifically, the basal culture medium solution is mixed with the mother liquor containing the compound of formula (II) and the mother liquor containing palmitoyl pentapeptide-4 for dilution until the concentration of the compound of formula (II) is 150 μg / mL and the concentration of palmitoyl pentapeptide-4 is 3 μg / mL, and then this sample can be obtained.

[0201] <Experiment 1: Cytotoxicity Detection>

[0202] The CCK8 (Cell Counting Kit CCK 8) kit was used to test the viability of HaCaT cells to detect the effects of the first to eighth compositions of the present application on cells.

[0203] The test method includes the following steps S101 to 104:

[0204] Step S101: Cell seeding.

[0205] Specifically, human immortalized keratinocytes (abbreviated as HaCaT) were taken and seeded at 1×10 4Inoculate at a density of cells / well into a 96-well plate, add 100 μL of complete medium to each well (the complete medium is DMEM medium containing 10% FBS and 1% penicillin / streptomycin), and then place it in an incubator (the incubator contains 5% CO 2 , at a temperature of 37 °C) and incubate for 24 h.

[0206] Step S102, drug administration treatment.

[0207] Specifically, when the cell confluence rate in the 96-well plate reaches 40% - 50%, divide the cells into a blank control group and at least 1 experimental group, and add 100 μL of the corresponding sample to each well; after drug administration, place it in an incubator (37 °C, 5% CO 2 ) and culture for 24 h.

[0208] Step S103, CCK8 detection.

[0209] After drug administration treatment, after the cells are incubated for 24 h, discard the supernatant, add 100 μL of CCK8 working solution (take 1 ml of CCK8 mother solution (Beyotime C0040 Cell Counting Kit-8 (CCK-8 kit)) and add it to 9 ml of DMEM, then 10 ml of CCK8 working solution can be prepared), incubate at 37 °C in the dark for 2 h. After the incubation ends, read the OD value at 450 nm, and use the OD value as the relative viability of the cells in each group.

[0210] Step S104, calculate the cell survival rate of each experimental group.

[0211] Set the cell survival rate of the blank control group as 100% as a benchmark, and further determine the cell survival rate of each experimental group. The calculation formula for the cell survival rate of each experimental group is as follows:

[0212] Cell survival rate = [(OD experimental well - OD zero adjustment well) / (OD control well - OD zero adjustment well)] × 100%;

[0213] Among them, OD experimental well is the absorbance value of the experimental group, OD control well is the absorbance value of the blank control group, and OD zero adjustment well is the absorbance value of the calculation control group.

[0214] The absorbance value of the calculation control group can be determined according to the following method: Set a zero adjustment well without cells in the 96-well plate, only add 1X CCK-8 working solution, and read the OD value at 450 nm as the absorbance value of the calculation control group.

[0215] <Experimental Example 1-1>

[0216] Experimental Example 1-1 is mainly used to verify the effect of the first composition on cell viability. The first composition includes the compound shown in formula (I) and palmitoyl tripeptide-5. The mass ratio of the compound shown in formula (I) to palmitoyl tripeptide-5 is 12.5:(0.15 - 1.5), that is, 25:(0.3 - 3).

[0217] The experiment was carried out according to the cell viability detection experimental method shown in steps S101 - 104. Among them, in step S102, the cells in the 96-well plate were divided into a blank control group and 5 experimental groups. The 5 experimental groups were Experimental Group 1-1, Experimental Group 1-2, Experimental Group 1-3, Experimental Group 1-4, and Experimental Group 1-5. The samples added to the blank control group, Experimental Group 1-1, Experimental Group 1-2, Experimental Group 1-3, Experimental Group 1-4, and Experimental Group 1-5 were: blank control group sample, Sample 1-1, Sample 1-2, Sample 1-3, Sample 1-4, and Sample 1-5 respectively.

[0218] Experimental Results and Analysis

[0219] The experimental results are shown in Table 1-1.

[0220] Table 1-1

[0221]

[0222]

[0223] According to Table 1-1, when the first composition acts on cells, it has good cell viability and will not cause adverse effects on cells.

[0224] <Experimental Example 1-2>

[0225] Experimental Example 1-2 is mainly used to verify the effect of the second composition on cell viability. The second composition includes the compound shown in formula (I) and acetyl dipeptide-1 cetyl ester. The mass ratio of the compound shown in formula (I) to acetyl dipeptide-1 cetyl ester is 12.5:(0.25 - 2), that is, 25:(0.5 - 4).

[0226] The experiment was carried out according to the cell viability detection experimental method shown in steps S101 - 104. Among them, in step S102, the cells in the 96-well plate were divided into a blank control group and 5 experimental groups. The 5 experimental groups were Experimental Group 1-2-1, Experimental Group 1-2-2, Experimental Group 1-2-3, Experimental Group 1-2-4, and Experimental Group 1-2-5. The samples added to the blank control group, Experimental Group 1-2-1, Experimental Group 1-2-2, Experimental Group 1-2-3, Experimental Group 1-2-4, and Experimental Group 1-2-5 were: blank control group sample, Sample 2-1, Sample 2-2, Sample 2-3, Sample 2-4, and Sample 2-5 respectively.

[0227] Experimental results and analysis

[0228] The experimental results are shown in Table 1-2.

[0229] Table 1-2

[0230]

[0231]

[0232] As can be seen from Table 1-2, when the second composition acts on cells, it has good cell viability and will not cause adverse effects on cells.

[0233] <Experimental Example 1-3>

[0234] Experimental Example 1-3 is mainly used to verify the effect of the third composition on cell viability. The third composition includes the compound shown in formula (I) and acetyl tripeptide-30 citrulline. The mass ratio of the compound shown in formula (I) to acetyl tripeptide-30 citrulline is 12.5:(0.25 - 1.5), that is, 25:(0.5 - 3).

[0235] The experiment was carried out according to the cell viability detection experimental method shown in steps S101 - 104. Among them, in step S102, the cells in the 96-well plate were divided into a blank control group and 5 experimental groups. The 5 experimental groups were Experimental Group 1-3-1, Experimental Group 1-3-2, Experimental Group 1-3-3, Experimental Group 1-3-4, and Experimental Group 1-3-5. The samples added to the blank control group, Experimental Group 1-3-1, Experimental Group 1-3-2, Experimental Group 1-3-3, Experimental Group 1-3-4, and Experimental Group 1-3-5 were: blank control group sample, Sample 3-1, Sample 3-2, Sample 3-3, Sample 3-4, and Sample 3-5.

[0236] Experimental results and analysis

[0237] The experimental results are shown in Table 1-3.

[0238] Table 1-3

[0239]

[0240]

[0241] As can be seen from Table 1-3, when the third composition acts on cells, it has good cell viability and will not cause adverse effects on cells.

[0242] <Experimental Example 1-4>

[0243] Experimental Example 1-4 is mainly used to verify the effect of the fourth composition on cell viability. The fourth composition includes the compound shown in formula (I) and palmitoyl pentapeptide-4. The mass ratio of the compound shown in formula (I) to palmitoyl pentapeptide-4 is 12.5:(0.025 - 0.25), that is, 25:(0.05 - 0.5).

[0244] The experiment was carried out according to the cell viability detection experimental method shown in steps S101 - 104. Among them, in step S102, the cells in the 96-well plate were divided into a blank control group and 5 experimental groups. The 5 experimental groups were Experimental Group 1-4-1, Experimental Group 1-4-2, Experimental Group 1-4-3, Experimental Group 1-4-4, and Experimental Group 1-4-5. The samples added to the blank control group, Experimental Group 1-4-1, Experimental Group 1-4-2, Experimental Group 1-4-3, Experimental Group 1-4-4, and Experimental Group 1-4-5 were: blank control group sample, Sample 4-1, Sample 4-2, Sample 4-3, Sample 4-4, and Sample 4-5 respectively.

[0245] Experimental results and analysis

[0246] The experimental results are shown in Table 1-4.

[0247] Table 1-4

[0248]

[0249] It can be seen from Table 1-4 that when the fourth composition acts on cells, it has good cell viability and will not cause adverse effects on cells.

[0250] <Experimental Example 1-5>

[0251] Experimental Example 1-5 is mainly used to verify the effect of the fifth composition on cell viability. The fifth composition includes the compound shown in formula (II) and palmitoyl tripeptide-5. The mass ratio of the compound shown in formula (II) to palmitoyl tripeptide-5 is 150:(1.8 - 18), that is, 25:(0.3 - 3).

[0252] The experiment was carried out according to the cell viability detection experimental method shown in steps S101 - 104. Among them, in step S102, the cells in the 96-well plate were divided into a blank control group and 5 experimental groups. The 5 experimental groups were Experimental Group 1-5-1, Experimental Group 1-5-2, Experimental Group 1-5-3, Experimental Group 1-5-4, and Experimental Group 1-5-5. The samples added to the blank control group, Experimental Group 1-5-1, Experimental Group 1-5-2, Experimental Group 1-5-3, Experimental Group 1-5-4, and Experimental Group 1-5-5 were: blank control group sample, Sample 5-1, Sample 5-2, Sample 5-3, Sample 5-4, and Sample 5-5 respectively.

[0253] Experimental results and analysis

[0254] The experimental results are shown in Table 1-5.

[0255] Table 1-5

[0256]

[0257]

[0258] As can be seen from Table 1-5, when the fifth composition acts on cells, it has good cell viability and will not cause adverse effects on cells.

[0259] <Experimental Example 1-6>

[0260] Experimental Example 1-6 is mainly used to verify the effect of the sixth composition on cell viability. The sixth composition includes the compound shown in formula (II) and acetyl dipeptide-1 cetyl ester. The mass ratio of the compound shown in formula (II) to acetyl dipeptide-1 cetyl ester is 150:(3-24), that is, 25:(0.5-4).

[0261] The experiment was carried out according to the cell viability detection experimental method shown in steps S101-104. Among them, in step S102, the cells were divided into a blank control group and 5 experimental groups. The 5 experimental groups were Experimental Group 1-6-1, Experimental Group 1-6-2, Experimental Group 1-6-3, Experimental Group 1-6-4 and Experimental Group 1-6-5. The samples added to the blank control group, Experimental Group 1-6-1, Experimental Group 1-6-2, Experimental Group 1-6-3, Experimental Group 1-6-4 and Experimental Group 1-6-5 were: blank control group sample, Sample 6-1, Sample 6-2, Sample 6-3, Sample 6-4 and Sample 6-5.

[0262] Experimental results and analysis

[0263] The experimental results are shown in Table 1-6.

[0264] Table 1-6

[0265]

[0266]

[0267] As can be seen from Table 1-6, when the first composition acts on cells, it has good cell viability and will not cause adverse effects on cells.

[0268] <Experimental Example 1-7>

[0269] Experimental Example 1-7 is mainly used to verify the effect of the seventh composition on cell viability. The seventh composition includes the compound shown in formula (II) and acetyl tripeptide-30 citrulline. The mass ratio of the compound shown in formula (II) to acetyl tripeptide-30 citrulline is 150:(3-18), that is, 25:(0.5-3).

[0270] The experiment was carried out according to the cell viability detection experimental method shown in steps S101-104. Among them, in step S102, the cells were divided into a blank control group and 5 experimental groups. The 5 experimental groups were Experimental Group 1-7-1, Experimental Group 1-7-2, Experimental Group 1-7-3, Experimental Group 1-7-4 and Experimental Group 1-7-5. The samples added to the blank control group, Experimental Group 1-7-1, Experimental Group 1-7-2, Experimental Group 1-7-3, Experimental Group 1-7-4 and Experimental Group 1-7-5 were: blank control group sample, Sample 7-1, Sample 7-2, Sample 7-3, Sample 7-4 and Sample 7-5 respectively.

[0271] Experimental results and analysis

[0272] The experimental results are shown in Table 1-7.

[0273] Table 1-7

[0274]

[0275]

[0276] It can be seen from Table 1-7 that when the third composition acts on cells, it has good cell viability and will not cause adverse effects on cells.

[0277] <Experimental Example 1-8>

[0278] Experimental Example 1-8 is mainly used to verify the effect of the eighth composition on cell viability. The eighth composition includes the compound shown in formula (II) and palmitoyl pentapeptide-4. The mass ratio of the compound shown in formula (II) to palmitoyl pentapeptide-4 is 150:(0.3-3), that is, 25:(0.05-0.5).

[0279] The experiment was carried out according to the cell viability detection experimental method shown in steps S101-104. Among them, in step S102, the cells were divided into a blank control group and 5 experimental groups. The 5 experimental groups were Experimental Group 1-8-1, Experimental Group 1-8-2, Experimental Group 1-8-3, Experimental Group 1-8-4 and Experimental Group 1-8-5. The samples added to the blank control group, Experimental Group 1-8-1, Experimental Group 1-8-2, Experimental Group 1-8-3, Experimental Group 1-8-4 and Experimental Group 1-8-5 were: blank control group sample, Sample 8-1, Sample 8-2, Sample 8-3, Sample 8-4 and Sample 8-5 respectively.

[0280] Experimental results and analysis

[0281] The experimental results are shown in Table 1-8.

[0282] Table 1-8

[0283]

[0284] As can be seen from Table 1-8, when the eighth composition acts on cells, it has good cell viability and will not cause adverse effects on cells.

[0285] <Experiment 2, mRNA Expression Detection>

[0286] Samples prepared using the first to eighth compositions provided in the embodiments of the present application were used to administer drugs to HaCaT cells treated with UVB irradiation respectively, and then the mRNA expression levels of the target genes (the target genes are SLC7A11 gene or HBGM1 gene) of HaCaT cells were detected to analyze the anti-UVB efficacy of the first to eighth compositions.

[0287] The experimental method includes the following steps S201 to S204.

[0288] S201. Cell seeding:

[0289] Specifically, human immortalized keratinocytes (abbreviated as HaCaT) were taken and seeded into a 6-well plate at an inoculation density of 80×10 4 cells / well, and 2000 μL of complete medium (the complete medium is DMEM medium containing 10% FBS and 1% penicillin / streptomycin) was added to each well; then it was incubated in an incubator (the incubator contains 5% CO 2 , and the temperature is 37°C) for 24 h.

[0290] S202. Drug administration:

[0291] When the cell confluence rate in the 6-well plate reached 70% - 80%, the cells were divided into a blank control group, a UVB control group and at least one experimental group;

[0292] Except for the blank control group, the UVB control group and all experimental groups were irradiated with a UVB dose of 50 mJ / cm 2 ; subsequently, the media of the blank control group, the UVB control group and each experimental group were discarded, and the corresponding treatment substances were added to each group for drug administration. Each group was set with 5 replicate wells, and after the drug administration was completed, it was placed in an incubator (37°C, 5% CO 2 ) for culture for 24 h.

[0293] S203. RNA extraction:

[0294] After culturing for 24 h, RNA was extracted from the cells in each group, which specifically included the following steps S2031-S20310.

[0295] S2031. After culturing for 24 h, pour out the culture medium and rinse once with PBS. Add 1 ml of TransZol Up to every 10 cm 2 growing cultured cells, place horizontally for a moment to evenly distribute the lysate on the cell surface and lyse the cells, and then use a pipette to pipette the cells to make them detached. Transfer the cell lysate to a centrifuge tube, add 0.2 ml of RNA Extraction Agent, and repeatedly pipette with a pipette until there is no obvious precipitate in the lysate, and vortex at room temperature for 5 minutes.

[0296] S2032. Centrifuge at a speed of 10,000 g and a temperature of 2-8 °C for 15 minutes. At this time, the sample is divided into three layers: a colorless aqueous phase (upper layer), an intermediate layer, and a pink organic phase (lower layer); among them, RNA is in the aqueous phase, and the volume of the aqueous phase is about 50%-60% of the TransZol Up reagent used.

[0297] S2033. Transfer the colorless aqueous phase to a new centrifuge tube, add an equal volume of absolute ethanol, and gently invert and mix.

[0298] S2034. Add the obtained solution and precipitate together to a centrifugal column, centrifuge at a speed of 12,000 g at room temperature for 30 seconds, and discard the effluent.

[0299] S2035. Then add 500 μl of CB9 (Clean Buffer 9), centrifuge at a speed of 12,000 g at room temperature for 30 seconds, discard the effluent, and then repeat this step once.

[0300] S2036. Then add 500 μl of WB9 (Wash Buffer 9), centrifuge at a speed of 12,000 g at room temperature for 30 seconds, discard the effluent, and repeat this step once.

[0301] S2037. Centrifuge at a speed of 12,000 g at room temperature for 2 minutes to completely remove the residual ethanol.

[0302] S2038. Place the centrifugal column in an RNase-free Tube, add 50-200 μl of RNase-free Water in the center of the centrifugal column, and let it stand at room temperature for 1 minute.

[0303] S2039. Centrifuge at a speed of 12,000 g at room temperature for 1 minute to elute the RNA.

[0304] S20310. Use a micro-spectrophotometer (Thermo Scientific NanoDrop) to measure the concentration of RNA, obtain RNA samples with measured concentrations in each group, and store them at -80°C.

[0305] S204. Perform qPCR on the RNA samples with measured concentrations in each group to determine the relative expression level of mRNA of the target gene.

[0306] Step S204 specifically includes steps S2041 to S2043:

[0307] S2041. Reverse transcribe the RNA samples of each group with measured concentration to obtain reverse transcribed samples.

[0308] Specifically, reverse transcription was performed using RT-PCR reaction: the RNA sample with measured concentration was used to calculate the corresponding RNA volume based on the amount of 2ug, and then the corresponding volume of RNase Free H2O was added. 2 O) and reverse transcriptase mix, the total volume of the RT-PCR reaction system was 20 μL.

[0309] The specific system of RT-PCR reaction can be found in Table 2-1, and the specific procedure of RT-PCR reaction can be found in Table 2-2.

[0310] Table 2-1. RT-PCR reaction system

[0311] Name Volume RNA 2ug <![CDATA[RNase Free H 2 O]]> Up to 20μL 5X Evo M-MLV RT Master Mix 4μL

[0312] Table 2-2. Procedure for RT-PCR reaction

[0313]

[0314]

[0315] S2042. Then dilute 20 μL of the reverse transcription sample to 400 μL to obtain a cDNA sample with a final concentration of 5 ng / μL.

[0316] S2043. Take cDNA samples for qPCR reaction and analyze the relative expression level of mRNA of the gene to be tested corresponding to each group.

[0317] Specifically, cDNA samples were used as cDNA templates for qPCR reactions. For each gene in each cDNA sample, three replicates were performed for detection. After sample addition, the qPCR program was run on the machine. After the qPCR reaction, the reaction data was processed, and the 2-△△Ct method was used to analyze the relative mRNA expression levels of the target genes in each group. T-TEST statistical analysis was performed on the data between groups. P < 0.05 indicates significant differences and statistical significance.

[0318] Among them, the volume of each well in the qPCR reaction system was 10 μL, which can be referred to in Table 2-3;

[0319] The qPCR reaction program can be referred to in Table 2-4.

[0320] Table 2-3, qPCR reaction system

[0321] Name Volume cDNA template 4μL 2X qPCR SYBR Green Master Mix 5μL <![CDATA[Double distilled water (ddH 2 O)]]> 0.4μL 10uM primer (forward + reverse) 0.6μL

[0322] Table 2-4, qPCR reaction program

[0323]

[0324]

[0325] <Experimental Example 2-1>

[0326] Experimental Example 2-1 was mainly used to verify the anti-UVB damage effect of the first composition. The first composition includes the compound shown in formula (I) and palmitoyl tripeptide-5. The mass ratio of the compound shown in formula (I) to palmitoyl tripeptide-5 is 12.5:(0.15 - 1.5), that is, 25:(0.3 - 3).

[0327] The experiment was carried out according to the experimental method shown in the foregoing steps S201 - 204; among them,

[0328] In step S202, the cells were divided into a blank control group, a UVB control group, and five experimental groups, namely Experimental Group 2-1-1, Experimental Group 2-1-2, Experimental Group 2-1-3, Experimental Group 2-1-4, and Experimental Group 2-1-5. The samples added to the blank control group, the UVB control group, Experimental Group 2-1-1, Experimental Group 2-1-2, Experimental Group 2-1-3, Experimental Group 2-1-4, and Experimental Group 2-1-5 were: blank control group sample, UVB control group sample, Sample 1-1, Sample 1-2, Sample 1-3, Sample 1-4, and Sample 1-5;

[0329] In addition, the target gene for each group in the experiment was the HBGM1 gene.

[0330] Experimental results and analysis :

[0331] After obtaining the relative expression levels (i.e., relative expression amounts) of HBGM1 in each group, the expression inhibition rate (%) of HBGM1 in each experimental group relative to the UVB control group was calculated according to formula (a).

[0332] Formula (a) is:

[0333] Expression inhibition rate of HBGM1 (%) = (Relative expression amount of HBGM1 in the experimental group - Relative expression amount of HBGM1 in the UVB control group) / Relative expression amount of HBGM1 in the UVB control group.

[0334] When calculating according to formula (a), the average value of the relative expression amount of HBGM1 was substituted for calculation.

[0335] The experimental results are shown in Table 2-5.

[0336] Table 2-5

[0337]

[0338] From the above results, it can be seen that:

[0339] Relative to the UVB control group, when the experimental group 2-1-1 used the compound of formula (I) at a concentration of 12.5 μg / mL alone, the expression of HBGM1 was approximately inhibited by 16.51%.

[0340] Relative to the UVB control group, when the experimental groups 2-1-2 and 2-1-3 used palmitoyl tripeptide-5 at concentrations of 0.15 μg / mL and 1.5 μg / mL respectively alone, the expressions of HBGM1 were approximately inhibited by 3.21% and 8.21% respectively.

[0341] And according to the comparison results of the experimental groups 2-1-4 and 2-1-5 with the UVB control group, when the compound of formula (I) at 12.5 μg / mL was used in combination with palmitoyl tripeptide-5 at concentrations of 0.15 μg / mL and 1.5 μg / mL respectively, the expressions of HBGM1 were approximately inhibited by 48% and 32% respectively.

[0342] From the above, it can be seen that for skin cells (HaCaT cells) irradiated with UVB, the first composition containing the compound shown in formula (I) and palmitoyl tripeptide-5 can significantly inhibit the expression of HBGM1 and reduce the damage to the skin caused by UVB irradiation.

[0343] <Experimental Example 2-2>

[0344] Experimental Example 2-2 is mainly used to verify the anti-UVB damage effect of the second composition. The second composition includes the compound shown in formula (I) and acetyl dipeptide-1 cetyl ester. The mass ratio of the compound shown in formula (I) to acetyl dipeptide-1 cetyl ester is 12.5:(0.25-2), that is, 25:(0.5-4).

[0345] The experiment was carried out according to the experimental method shown in the foregoing steps S201 to S204; among them,

[0346] In step S202, the cells were divided into a blank control group, a UVB control group and 5 experimental groups. The 5 experimental groups were Experimental Group 2-2-1, Experimental Group 2-2-2, Experimental Group 2-2-3, Experimental Group 2-2-4 and Experimental Group 2-2-5. The samples added to the blank control group, the UVB control group, Experimental Group 2-1, Experimental Group 2-2-2, Experimental Group 2-2-3, Experimental Group 2-2-4 and Experimental Group 2-2-5 were: blank control group sample, UVB control group sample, Sample 2-1, Sample 2-2, Sample 2-3, Sample 2-4 and Sample 2-5;

[0347] In addition, the target gene in each group of the experiment was the HBGM1 gene.

[0348] Experimental results and analysis :

[0349] After obtaining the relative expression level (i.e., relative expression amount) of HBGM1 in each group, according to formula (a), the expression inhibition rate (%) of HBGM1 in each experimental group relative to the UVB control group was calculated.

[0350] Formula (a) is:

[0351] Expression inhibition rate of HBGM1 (%) = (relative expression amount of HBGM1 in the experimental group - relative expression amount of HBGM1 in the UVB control group) / relative expression amount of HBGM1 in the UVB control group.

[0352] When calculating according to formula (a), the relative expression amount of HBGM1 was substituted into the calculation after taking the average value.

[0353] The experimental results are shown in Table 2-6.

[0354] Table 2-6

[0355]

[0356] From the above results, it can be seen that:

[0357] Relative to the UVB control group, when Experimental Group 2-2-1 used the compound of formula (I) at a concentration of 12.5 μg / mL alone, the expression of HMGB1 was approximately inhibited by 14.69%,

[0358] When acetyl dipeptide-1 cetyl ester with a concentration of 0.25 μg / mL and 2.0 μg / mL was used separately in Experimental Group 2-2-2 and Experimental Group 2-2-3 compared with the UVB control group, the expression of HMGB1 was inhibited by approximately 13.74% and 12.8% respectively.

[0359] According to the comparison results between Experimental Group 2-2-4, Experimental Group 2-2-5 and the UVB control group, when the compound of formula (I) at 12.5 μg / mL was used in combination with acetyl dipeptide-1 cetyl ester at a concentration of 0.25 μg / mL and 2.0 μg / mL respectively, the expression of HBGM1 was inhibited by approximately 48% and 61%.

[0360] As can be seen from the above, for skin cells (HaCaT cells) irradiated with UVB, the second composition containing the compound of formula (I) and acetyl dipeptide-1 cetyl ester can significantly inhibit the expression of HBGM1 and reduce the damage to the skin caused by UVB irradiation.

[0361] <Experimental Example 2-3>

[0362] Experimental Example 2-3 is mainly used to verify the anti-UVB damage effect of the third composition. The third composition includes the compound of formula (I) and acetyl tripeptide-30 citrulline, and the mass ratio of the compound of formula (I) to acetyl tripeptide-30 citrulline is 12.5:(0.25 - 1.5), that is, 25:(0.5 - 3).

[0363] The experiment was carried out according to the experimental method shown in the foregoing steps S201 - 204; among them,

[0364] In step S202, the cells were divided into a blank control group, a UVB control group and 5 experimental groups. The 5 experimental groups were Experimental Group 2-3-1, Experimental Group 2-3-2, Experimental Group 2-3-3, Experimental Group 2-3-4 and Experimental Group 2-3-5. The samples added to the blank control group, UVB control group, Experimental Group 2-3-1, Experimental Group 2-3-2, Experimental Group 2-3-3, Experimental Group 2-3-4 and Experimental Group 2-3-5 were: blank control group sample, UVB control group sample, Sample 3-1, Sample 3-2, Sample 3-3, Sample 3-4 and Sample 3-5;

[0365] In addition, the target gene of each group in the experiment was the HBGM1 gene.

[0366] Experimental results and analysis :

[0367] After obtaining the relative expression level (i.e., relative expression amount) of HBGM1 in each group, according to formula (a), the expression inhibition rate (%) of HBGM1 in each experimental group relative to the UVB control group was calculated.

[0368] Formula (a) is as follows:

[0369] Inhibitory rate of HBGM1 expression (%) = (Relative expression level of HBGM1 in the experimental group - Relative expression level of HBGM1 in the UVB control group) / Relative expression level of HBGM1 in the UVB control group.

[0370] When calculating according to formula (a), the average value of the relative expression level of HBGM1 is taken for substitution calculation.

[0371] The experimental results are shown in Table 2-7.

[0372] Table 2-7

[0373]

[0374] As can be seen from the above:

[0375] Compared with the UVB control group, when the experimental group 2-3-1 used the compound of formula (I) alone at a concentration of 12.5 μg / mL, the expression of HBGM1 was approximately inhibited by 13.02%.

[0376] Compared with the UVB control group, when the experimental groups 2-3-2 and 2-3-3 used acetyl tripeptide-30 citrulline alone at concentrations of 0.25 μg / mL and 1.5 μg / mL respectively, the expressions of HBGM1 were approximately inhibited by 5.42% and 8.02% respectively.

[0377] According to the comparison results of the experimental groups 2-3-4 and 2-3-5 with the UVB control group, when the compound of formula (I) at 12.5 μg / mL was used in combination with acetyl tripeptide-30 citrulline at concentrations of 0.25 μg / mL and 1.5 μg / mL respectively, the expressions of HBGM1 were approximately inhibited by 40% and 35%.

[0378] As can be seen from the above, for the skin cells (HaCaT cells) irradiated with UVB, the first composition containing the compound shown in formula (I) and acetyl tripeptide-30 citrulline can significantly inhibit the expression of HBGM1 and reduce the damage to the skin caused by UVB irradiation.

[0379] <Experimental Example 2-4>

[0380] Experimental Example 2-4 is mainly used to verify the anti-UVB damage effect of the fourth composition. The fourth composition includes the compound shown in formula (I) and palmitoyl pentapeptide-4. The mass ratio of the compound shown in formula (I) to palmitoyl pentapeptide-4 is 12.5:(0.025 - 0.25), that is, 25:(0.05 - 0.5).

[0381] Perform experiments according to the experimental methods shown in the foregoing steps S201 to S204; among them,

[0382] In step S202, the cells are divided into a blank control group, a UVB control group, and five experimental groups. The five experimental groups are experimental group 2-4-1, experimental group 2-4-2, experimental group 2-4-3, experimental group 2-4-4, and experimental group 2-4-5. The samples added to the blank control group, the UVB control group, experimental group 2-4-1, experimental group 2-4-2, experimental group 2-4-3, experimental group 2-4-4, and experimental group 2-4-5 are: blank control group sample, UVB control group sample, sample 4-1, sample 4-2, sample 4-3, sample 4-4, and sample 4-5;

[0383] In addition, the target gene of each group in the experiment is the HBGM1 gene.

[0384] Experimental results and analysis :

[0385] After obtaining the relative expression levels (i.e., relative expression amounts) of HBGM1 in each group, calculate the expression inhibition rate (%) of HBGM1 in each experimental group relative to the UVB control group according to formula (a).

[0386] Formula (a) is:

[0387] Expression inhibition rate of HBGM1 (%) = (relative expression amount of HBGM1 in the experimental group - relative expression amount of HBGM1 in the UVB control group) / relative expression amount of HBGM1 in the UVB control group.

[0388] When calculating according to formula (a), the relative expression amount of HBGM1 is substituted for calculation by taking the average value.

[0389] The experimental results are shown in Table 2-8.

[0390] Table 2-8

[0391]

[0392] From the above results, it can be seen that:

[0393] Relative to the UVB control group, when experimental group 2-4-1 uses the compound of formula (I) alone at a concentration of 12.5 μg / mL, the expression of HBGM1 is approximately inhibited by 17.57%.

[0394] Relative to the UVB control group, when experimental group 2-4-2 and experimental group 2-4-3 use palmitoyl pentapeptide-4 alone at a concentration of 0.025 μg / mL and a concentration of 0.25 μg / mL, respectively, the expressions of HBGM1 are approximately inhibited by 19.22% and 5.32%, respectively.

[0395] According to the comparison results of Experimental Group 2-4-4, Experimental Group 2-4-5 and the UVB control group, when the compound of formula (I) at 12.5 μg / mL is compounded with palmitoyl pentapeptide-4 at concentrations of 0.025 μg / mL and 0.25 μg / mL respectively, the expression of HBGM1 is inhibited by approximately 56% and 45%.

[0396] As can be seen from the above, for skin cells (HaCaT cells) irradiated with UVB, the first composition containing the compound of formula (I) and palmitoyl pentapeptide-4 can significantly inhibit the expression of HBGM1 and reduce the damage to the skin caused by UVB irradiation.

[0397] In summary, after UVB irradiation, the expression level of HBGM1 increases significantly. When the compound of formula (I) is compounded with palmitoyl tripeptide-5, acetyl dipeptide-1 cetyl ester, acetyl tripeptide-30 citrulline, and palmitoyl pentapeptide-4 respectively within a specific ratio range, the expression level of HBGM1 can be significantly reduced. Moreover, the compounding of the compound of formula (I) and palmitoyl tripeptide-5 shows an additional synergistic effect compared to the case of using the compound of formula (I) or palmitoyl tripeptide-5 alone.

[0398] Therefore, the compounding of the compound of formula (I) with palmitoyl tripeptide-5, acetyl dipeptide-1 cetyl ester, acetyl tripeptide-30 citrulline, and palmitoyl pentapeptide-4 can significantly reduce the expression level of HBGM1, indicating that the compounding of the compound of formula (I) with palmitoyl tripeptide-5, acetyl dipeptide-1 cetyl ester, acetyl tripeptide-30 citrulline, and palmitoyl pentapeptide-4 can be particularly effective in resisting DNA damage caused by UVB.

[0399] <Experimental Example 2-5>

[0400] Experimental Example 2-5 is mainly used to verify the anti-UVB damage effect of the fifth composition. The fifth composition includes the compound of formula (II) and palmitoyl tripeptide-5, and the mass ratio of the compound of formula (II) to palmitoyl tripeptide-5 is 150:(1.8 - 18), that is, 25:(0.3 - 3).

[0401] The experiment was carried out according to the experimental method shown in the foregoing steps S201 - 204; among them,

[0402] In step S202, the cells are divided into a blank control group, a UVB control group, and five experimental groups, namely experimental group 2-5-1, experimental group 2-5-2, experimental group 2-5-3, experimental group 2-5-4, and experimental group 2-5-5. The samples added to the blank control group, the UVB control group, experimental group 2-5-1, experimental group 2-5-2, experimental group 2-5-3, experimental group 2-5-4, and experimental group 2-5-5 are: blank control group sample, UVB control group sample, sample 5-1, sample 5-2, sample 5-3, sample 5-4, and sample 5-5;

[0403] In addition, the target gene for each group in the experiment is the SLC7A11 gene.

[0404] Experimental results and analysis :

[0405] After obtaining the relative expression levels (i.e., relative expression amounts) of SLC7A11 in each group, the expression improvement rate (%) of SLC7A11 in each experimental group relative to the UVB control group is calculated according to formula (b).

[0406] Formula (b) is:

[0407] Expression improvement rate of SLC7A11 (%) = (relative expression amount of SLC7A11 in the experimental group - relative expression amount of SLC7A11 in the UVB control group) / relative expression amount of SLC7A11 in the UVB control group.

[0408] When calculating according to formula (b), the average value of the relative expression amount of SLC7A11 is substituted for calculation.

[0409] The experimental results are shown in Table 2-9.

[0410] Table 2-9

[0411]

[0412] From the above results, it can be seen that:

[0413] Relative to the UVB treatment group, when the compound of formula (II) with a concentration of 150 μg / mL is used alone, the expression of SLC7A11 is increased by about 3%.

[0414] Relative to the UVB treatment group, when palmitoyl tripeptide-5 with a concentration of 1.8 μg / mL and a concentration of 18 μg / mL is used alone, the expression of SLC7A11 is increased by about 34% and decreased by about 6% respectively.

[0415] When compound (II) at a concentration of 150 μg / mL is compounded with palmitoyl tripeptide-5 at concentrations of 1.8 μg / mL and 18 μg / mL, the expression of SLC7A11 is significantly increased to approximately 88.57% and 85.71%.

[0416] As can be seen from the above, for skin cells (HaCaT cells) irradiated with UVB, the fifth composition containing the compound shown in formula (II) and palmitoyl tripeptide-5 can significantly increase the expression rate of HBGM1, promote the expression of HBGM1, and reduce the damage to the skin caused by UVB irradiation.

[0417] <Experimental Example 2-6>

[0418] Experimental Example 2-6 is mainly used to verify the anti-UVB damage effect of the sixth composition. The sixth composition includes the compound shown in formula (II) and acetyl dipeptide-1 cetyl ester. The mass ratio of the compound shown in formula (II) to acetyl dipeptide-1 cetyl ester is 150:(3-24), that is, 25:(0.5-4).

[0419] The experiment was carried out according to the experimental method shown in the foregoing steps S201 to S204; among them,

[0420] In step S202, the cells were divided into a blank control group, a UVB control group, and 5 experimental groups. The 5 experimental groups were Experimental Group 2-6-1, Experimental Group 2-6-2, Experimental Group 2-6-3, Experimental Group 2-6-4, and Experimental Group 2-6-5. The samples added to the blank control group, the UVB control group, Experimental Group 2-6-1, Experimental Group 2-6-2, Experimental Group 2-6-3, Experimental Group 2-6-4, and Experimental Group 2-6-5 were: blank control group sample, UVB control group sample, Sample 6-1, Sample 6-2, Sample 6-3, Sample 6-4, and Sample 6-5;

[0421] In addition, the target gene in each group of the experiment was the SLC7A11 gene.

[0422] Experimental results and analysis :

[0423] After obtaining the relative expression levels (i.e., relative expression amounts) of SLC7A11 in each group, the expression promotion rate (%) of SLC7A11 in each experimental group relative to the UVB control group was calculated according to formula (b).

[0424] Formula (b) is:

[0425] The expression promotion rate (%) of SLC7A11 = (the relative expression amount of SLC7A11 in the experimental group - the relative expression amount of SLC7A11 in the UVB control group) / the relative expression amount of SLC7A11 in the UVB control group.

[0426] When calculating according to formula (b), the relative expression level of SLC7A11 is averaged and substituted into the calculation.

[0427] The experimental results are shown in Table 2-10.

[0428] Table 2-10

[0429]

[0430]

[0431] From the above results, it can be seen that: compared with the UVB treatment group, when the compound of formula (II) with a concentration of 150 μg / mL is used alone, the expression of SLC7A11 is reduced by 3%.

[0432] Compared with the UVB treatment group, when acetyl dipeptide-1 cetyl ester with a concentration of 3 μg / mL and a concentration of 24 μg / mL is used alone, the expression of SLC7A11 is reduced.

[0433] When the compound of formula (II) with a concentration of 150 μg / mL is used in combination with acetyl dipeptide-1 cetyl ester with a concentration of 3 μg / mL and 24 μg / mL, the expression of SLC7A11 is greatly increased to about 26.3% and 39.5%.

[0434] From the above, it can be known that for skin cells (HaCaT cells) irradiated with UVB, the sixth composition containing the compound shown in formula (II) and acetyl dipeptide-1 cetyl ester can greatly increase the expression rate of HBGM1, promote the expression of HBGM1, and reduce the damage to the skin caused by UVB irradiation.

[0435] <Experimental Example 2-7>

[0436] Experimental Example 2-7 is mainly used to verify the anti-UVB damage effect of the seventh composition. The seventh composition includes the compound shown in formula (II) and acetyl tripeptide-30 citrulline. The mass ratio of the compound shown in formula (II) to acetyl tripeptide-30 citrulline is 150:(3-18), that is, 25:(0.5-3).

[0437] The experiment is carried out according to the experimental method shown in the foregoing steps S201 to S204; among them,

[0438] In step S202, the cells are divided into a blank control group, a UVB control group, and five experimental groups, namely experimental group 2-7-1, experimental group 2-7-2, experimental group 2-7-3, experimental group 2-7-4, and experimental group 2-7-5. The samples added to the blank control group, the UVB control group, experimental group 2-7-1, experimental group 2-7-2, experimental group 2-7-3, experimental group 2-7-4, and experimental group 2-7-5 are: blank control group sample, UVB control group sample, sample 7-1, sample 7-2, sample 7-3, sample 7-4, and sample 7-5;

[0439] In addition, the target gene of each group in the experiment is the SLC7A11 gene.

[0440] Experimental results and analysis :

[0441] After obtaining the relative expression levels (i.e., relative expression amounts) of SLC7A11 in each group, the expression improvement rate (%) of SLC7A11 in each experimental group relative to the UVB control group is calculated according to formula (b).

[0442] Formula (b) is:

[0443] Expression improvement rate of SLC7A11 (%) = (relative expression amount of SLC7A11 in the experimental group - relative expression amount of SLC7A11 in the UVB control group) / relative expression amount of SLC7A11 in the UVB control group.

[0444] When calculating according to formula (b), the average value of the relative expression amount of SLC7A11 is substituted for calculation.

[0445] The experimental results are shown in Table 2-11.

[0446] Table 2-11

[0447]

[0448] Relative to the UVB treatment group, when the compound of formula (II) with a concentration of 150 μg / mL is used alone, the expression of SLC7A11 is increased by 6%.

[0449] Relative to the UVB treatment group, when acetylated tripeptide-30 citrulline with concentrations of 3 μg / mL and 18 μg / mL is used alone, the expressions of SLC7A11 are increased by 10% and 23% respectively.

[0450] When the compound of formula (I) with a concentration of 150 μg / mL is compounded with acetylated tripeptide-30 citrulline with concentrations of 3 μg / mL and 18 μg / mL, the expressions of SLC7A11 are greatly increased to approximately 65% and 52%.

[0451] From the above, it can be seen that for skin cells (HaCaT cells) irradiated by UVB, the seventh composition containing the compound represented by formula (II) and acetyl tripeptide-30 citrulline can significantly increase the expression rate of HBGM1, promote the expression of HBGM1, and reduce the damage of UVB irradiation to the skin.

[0452] <Experimental Example 2-8>

[0453] Experimental Example 2-8 is mainly used to verify the anti-UVB damage effect of the eighth composition. The eighth composition includes the compound shown in formula (II) and palmitoyl pentapeptide-4. The mass ratio of the compound shown in formula (II) and palmitoyl pentapeptide-4 is 150: (0.3~3), that is, 25: (0.05~0.5).

[0454] The experiment is carried out according to the experimental method shown in the above steps S201 to S204; wherein,

[0455] In step S202, the cells are divided into a blank control group, a UVB control group and five experimental groups, the five experimental groups are experimental group 2-8-1, experimental group 2-8-2, experimental group 2-8-3, experimental group 2-8-4 and experimental group 2-8-5, and the samples added to the blank control group, UVB control group, experimental group 2-8-1, experimental group 2-8-2, experimental group 2-8-3, experimental group 2-8-4 and experimental group 2-8-5 are: blank control group sample, UVB control group sample, sample 8-1, sample 8-2, sample 8-3, sample 8-4 and sample 8-5;

[0456] In addition, the target gene of each group in the experiment was the SLC7A11 gene.

[0457] Experimental results and analysis :

[0458] After obtaining the relative expression level (ie, relative expression amount) of SLC7A11 in each group, the expression increase rate (%) of SLC7A11 in each experimental group relative to the UVB control group was calculated according to formula (b).

[0459] Formula (b) is:

[0460] The expression enhancement rate of SLC7A11 (%) = (relative expression level of SLC7A11 in the experimental group - relative expression level of SLC7A11 in the UVB control group) / relative expression level of SLC7A11 in the UVB control group.

[0461] When calculating according to formula (b), the relative expression level of SLC7A11 was taken as the average value and substituted into the calculation.

[0462] The experimental results are shown in Table 2-12.

[0463] Table 2-12

[0464]

[0465] From the above results, it can be seen that:

[0466] Compared with the UVB treatment group, when the compound of formula (II) was used alone at a concentration of 150 μg / mL, the expression of SLC7A11 increased by 5%.

[0467] Compared with the UVB treatment group, when palmitoyl pentapeptide-4 was used alone at concentrations of 0.3 μg / mL and 3 μg / mL, the expression of SLC7A11 increased by 13% and 8% respectively.

[0468] When the compound of formula (II) at a concentration of 150 μg / mL was compounded with palmitoyl pentapeptide-4 at concentrations of 0.3 μg / mL and 3 μg / mL, the expression of SLC7A11 increased significantly to approximately 74% and 87%.

[0469] From the above, it can be seen that for skin cells (HaCaT cells) irradiated with UVB, the seventh composition containing the compound shown in formula (II) and acetyl tripeptide-30 citrulline can significantly increase the expression rate of HBGM1, promote the expression of HBGM1, and reduce the damage to the skin caused by UVB irradiation.

[0470] In summary, after UVB irradiation, the expression level of SLC7A11 in skin cells (HaCaT cells) decreased significantly. When the compound of formula (II) was compounded with palmitoyl tripeptide-5, acetyl dipeptide-1 cetyl ester, acetyl tripeptide-30 citrulline, and palmitoyl pentapeptide-4 within a specific ratio range, the expression level of SLC7A11 could be significantly increased. Moreover, the compounding of the compound of formula (II) with palmitoyl tripeptide-5 showed an additional synergistic effect compared with the case of using the compound of formula (II) or palmitoyl tripeptide-5 alone.

[0471] Therefore, the compounding of the compound of formula (II) with palmitoyl tripeptide-5, acetyl dipeptide-1 cetyl ester, acetyl tripeptide-30 citrulline, and palmitoyl pentapeptide-4 can significantly increase the expression level of SLC7A11, indicating that the compounding of the compound of formula (II) with palmitoyl tripeptide-5, acetyl dipeptide-1 cetyl ester, acetyl tripeptide-30 citrulline, and palmitoyl pentapeptide-4 can be particularly effective in resisting oxidative stress caused by UVB.

[0472] <Application Example>

[0473] The composition provided in the embodiment of the present application can be used to prepare skin care products in the form of emulsions.

[0474] In the application example, the embodiment of the present application provides an emulsion. According to the components and their contents in the emulsion formulations shown in Tables 3-1 to 3-8, the emulsion can be prepared by the following emulsion preparation method.

[0475] Emulsion preparation method:

[0476] Heat phase A to 85°C and swell it evenly, and heat phase B to 85°C and dissolve it evenly;

[0477] Add the evenly swollen phase A to the evenly dissolved phase B and homogenize for 2 - 3 minutes to obtain a first mixture;

[0478] Add phase C to the first mixture and homogenize for 1 - 2 minutes to obtain a second mixture;

[0479] Stir and cool the second mixture to below 40°C, then add phase D and the dissolved phase E and stir evenly. After discharging, the emulsion is obtained.

[0480] Table 3-1, Emulsion formulation 1

[0481]

[0482] Table 3-2, Emulsion formulation 2

[0483]

[0484]

[0485] Table 3-3, Emulsion formulation 3

[0486]

[0487] Table 3-4, Emulsion formulation 4

[0488]

[0489]

[0490] Table 3-5, Emulsion formulation 5

[0491]

[0492] Table 3-6, Emulsion formulation 6

[0493]

[0494]

[0495] Table 3-7, Emulsion formulation 7

[0496]

[0497] Table 3-8, Emulsion Formula 8

[0498]

[0499]

[0500] The emulsions prepared above all contain the first compound and the second compound, and thus have the effects and uses of the said composition.

[0501] The above specific embodiments have described the present invention in detail, but these do not constitute a limitation to the present invention. The protection scope of the present invention is not limited to the above embodiments. Any equivalent modifications or changes made by those of ordinary skill in the art according to the disclosure of the present invention should be included in the protection scope recorded in the claims.

Claims

1. A composition having anti-UVB damage function, characterized in that: include: A first compound, the first compound is selected from the compounds represented by formula (I) or formula (II); Formula (I): Formula (II): and The second compound is selected from any one of palmitoyl tripeptide-5, acetyl dipeptide-1 cetyl ester, acetyl tripeptide-30 citrulline, and palmitoyl pentapeptide-4.

2. The composition according to claim 1, characterized in that The first compound is a compound represented by formula (I), the second compound is palmitoyl tripeptide-5, and the mass ratio of the compound represented by formula (I) to palmitoyl tripeptide-5 is 25:0.3-3; or The first compound is a compound represented by formula (I), the second compound is acetyl dipeptide-1 cetyl ester, and the mass ratio of the compound of formula (I) to acetyl dipeptide-1 cetyl ester is 25:0.5-4; or The first compound is a compound represented by formula (I), the second compound is acetyl tripeptide-30 citrulline, and the mass ratio of the compound of formula (I) to acetyl tripeptide-30 citrulline is 25:0.5-3; or The first compound is a compound represented by formula (I), the second compound is palmitoyl pentapeptide-4, and the mass ratio of the compound represented by formula (I) to palmitoyl pentapeptide-4 is 25:0.05-0.

5.

3. The composition according to claim 1, characterized in that The first compound is a compound represented by formula (II); the second compound is palmitoyl tripeptide-5, and the mass ratio of the compound of formula (II) to palmitoyl tripeptide-5 is 25:0.3-3; or The first compound is a compound represented by formula (II), the second compound is acetyl dipeptide-1 cetyl ester, and the mass ratio of the compound of formula (II) to acetyl dipeptide-1 cetyl ester is 25:0.5-4; or The first compound is a compound represented by formula (II), the second compound is acetyl tripeptide-30 citrulline, and the mass ratio of the compound of formula (II) to acetyl tripeptide-30 citrulline is 25:0.5-3; or The first compound is a compound represented by formula (II), the second compound is palmitoyl pentapeptide-4, and the mass ratio of the compound represented by formula (II) to palmitoyl pentapeptide-4 is 25:0.05-0.

5.

4. The composition according to claim 1, characterized in that Also included are solvents.

5. A skin care product, characterized in that: include: A first compound, the first compound is selected from the compounds represented by formula (I) or formula (II); Formula (I): Formula (II): and The second compound is selected from any one of palmitoyl tripeptide-5, acetyl dipeptide-1 cetyl ester, acetyl tripeptide-30 citrulline, and palmitoyl pentapeptide-4.

6. Use of the composition according to any one of claims 1 to 4 in the preparation of an anti-UVB damage preparation.

7. Use of the composition according to any one of claims 1 to 4 in the preparation of a DNA damage inhibitor.

8. Use of the composition according to claim 2 in the preparation of an HMGB1 expression inhibitor.

9. Use of the composition according to claim 3 in preparing an SLC7A11 expression promoter.

10. Use of the composition according to any one of claims 1 to 4 in the preparation of skin care products.

Images